Be Biopharma
Be Biopharma pioneers Engineered B Cell Medicines (BCMs) to treat Hemophilia B and other genetic diseases. Their BCM platform creates durable, titratable, and redosable therapeutics without preconditioning, offering sustained therapeutic protein levels. This innovative approach aims to revolutionize treatment for various diseases.
Buy Funded Startups lists
Funding Round: Series C
Funding Amount: $92M
Date: 15-Jan-2025
Investors: Nextech, ARCH Venture Partners, Atlas Venture, RA Capital Management, Alta Partners, Longwood Fund, Bristol Myers Squibb, Takeda Ventures
Markets: Biotechnology, Therapeutics, Cell Therapy, Pharmaceutical, Biopharma
HQ: Cambridge, Massachusetts, United States
Founded: 2020
Website: https://www.be.bio/
LinkedIn: https://www.linkedin.com/company/be-biopharma-inc/
Twitter: https://twitter.com/bebiopharma
Crunchbase: https://www.crunchbase.com/organization/be-biopharma
Leave a Comment
Comments
No comments yet.